Drug molecules targeting oxidative stress, immunity, cancer and inflammation
Colby Pharmaceuticals acquired Othera Pharmaceuticals in September 2012. Colby is a clinical company developing proprietary drug molecules targeting diseases related to oxidative stress, immunity, cancer, and inflammation.
We invest in the most promising early-stage, rapid-growth technology companies in the Mid-Atlantic region.
The Fund typically initially invests $500,000 to $3M, with up to $4-5M to support the company’s growth. The general partners are active investors. Companies benefit from the Fund’s introductions to customers, recruits, resellers, distributors, Board directors, investors, and service providers.